BiotechTube
Telum Therapeutics

Telum Therapeutics

Barcelona, Spain· Est.
telumtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Telum Therapeutics is a private, preclinical-stage biotech addressing the global antimicrobial resistance (AMR) crisis. Its core innovation is the APEXp® platform, which uses synthetic biology and AI to engineer phage lytic enzymes as targeted alternatives to traditional antibiotics. The company's pipeline targets high-priority, multidrug-resistant Gram-negative and Gram-positive pathogens, positioning it in a critical and growing market. As a pre-revenue entity, its success hinges on advancing its lead programs through clinical validation and securing strategic partnerships or funding.

Infectious DiseasesAntimicrobial Resistance

Technology Platform

APEXp®: A proprietary platform leveraging synthetic biology and artificial intelligence to engineer and optimize phage lytic enzymes (enzybiotics) for enhanced potency, precision, and stability against multidrug-resistant bacteria.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

The global AMR crisis creates a pressing, high-value market with strong regulatory incentives (e.g., QIDP, pull incentives).
Telum's enzybiotic platform offers a novel, potentially resistance-breaking mechanism that could command premium pricing for hospital-based infections.
Strategic partnerships with large pharma seeking to replenish antimicrobial pipelines present a significant opportunity for non-dilutive funding and development support.

Risk Factors

High technical risk associated with translating a novel platform and biologic modality into safe and effective human therapeutics.
Significant funding risk as a pre-revenue, preclinical company in a competitive investment landscape.
Regulatory uncertainty for a new class of antimicrobials and intense competition from other novel modalities targeting AMR.

Competitive Landscape

Telum competes in the novel antimicrobial space against companies developing phage therapies (e.g., Adaptive Phage Therapeutics), monoclonal antibodies (e.g., Aridis Pharmaceuticals), and other enzybiotic/lysine platforms (e.g., ContraFect, Lysovant). Its key differentiator is the integration of AI and synthetic biology into a proprietary platform (APEXp®) for rational design and optimization, aiming for best-in-class product profiles.

More companies in Spain →